Review article: The role of acid suppression in patients with non-erosive reflux disease or functional heartburn

Alimentary Pharmacology and Therapeutics

Volumn 23, Issue SUPPL. 1, 2006, Pages 33-39

  Devault, K R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

BARRETT ESOPHAGUS; BURNING SENSATION; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; EROSION; ESOPHAGITIS; ESOPHAGUS ACHALASIA; ESOPHAGUS DISEASE; ESOPHAGUS MOTILITY; EXPOSURE; FUNCTIONAL DISEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; PATHOPHYSIOLOGY; PH MEASUREMENT; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; RETROSTERNAL PAIN; REVIEW; SYMPTOM; TREATMENT RESPONSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGITIS, PEPTIC; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; HYDROGEN-ION CONCENTRATION; OMEPRAZOLE; PROTON PUMPS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33645510406     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.02798.x     Document Type: Review

References (49)

1. DeVault KR Castell DO Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease Am J Gastroenterol 2005 100 190 200
2. Coenraad M Masclee AAM Straathof JWA et al. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis Am J Gastroenterol 1998 93 1068 72
3. Lundell LR Dent J Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification Gut 1999 45 172 80
4. Martinez SD Malagon IB Garewal HS et al. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns Aliment Pharmacol Ther 2003 17 537 45
5. Vaezi MF Richter JE Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease Gastroenterology 1996 111 1192 9
6. Cicala M Emerenziani S Caviglia R et al. Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease Aliment Pharmcol Ther 2003 18 605 13
7. Rodriquez-Stanley S Robinson M Earnest DL et al. Esophageal hypersensitivity may be a major cause of heartburn Am J Gastroenterol 1999 94 628 31
8. Miwa H Minoo T Hojo M et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases Aliment Pharmacol Ther 2004 20 Suppl 1 112 7
9. Barlow WJ Orlando RC The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis Gastroenterology 2005 128 771 8
10. Marrero JM de Caestecker JS Maxwell JD Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease Gut 1994 35 447 50
11. Meyer JH Lembo A Elashoff JE et al. Duodenal fat intensifies the perception of heartburn Gut 2001 49 624 8
12. Fass R Malagan IB Naliboff B et al. Effect of psychologically induced stress on symptom perception and autonomic nervous system response of patients with erosive esophagitis and non-erosive reflux disease Gastroenterology 2000 118 A637
13. Frazzoni M DeMicheli E Savarino V Different patterns of oesophageal acid exposure distinguish complicated reflux disease from either erosive oesophagitis or non-erosive reflux disease Aliment Pharmacol Ther 2003 18 1091 8
14. Venables TL Newland RD Patel AC et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice Scand J Gastroenterol 1997 32 965 73
15. Collen MJ Gastroesophageal reflux disease in the elderly: more severe = disease that requires more aggressive therapy Am J Gastroenterol 1995 90 1053 7
16. Ang TL Fock KM Ng TM Teo EK Tan J Gan LH The clinical and psychiatric differences between erosive and non-erosive reflux disease in an urban Asian population Gastroenterology 2003 124 Suppl 1 A-167 (abstract)
17. Carlsson R Dent J Watts R et al. Gastro-oesopahgeal reflux disease in primary care: an international study of different treatment strategies with omeprazole Eur J Gastroenterol Hepatol 1998 10 119 24
18. Farley A Wruble LD Humphries TJ Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Rabeprazole study group Am J Gastroenterol 2000 95 1894 9
19. Richter JE Kahrilas PJ Johaanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis. A randomized controlled trial Am J Gastroenterol 2001 96 656 65
20. Johnson DA Benjamin SB Vakil NB et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety Am J Gastroenterol 2001 96 27 34
21. Zaninotto G Molena D Ancona E A prospective multicenter study on laparoscopic treatment of gastroesophageal reflux disease in Italy Surg Endosc 2000 14 282 88
22. Dekkers CPM Beker JA Thjodleifsson B et al. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease Aliment Phamacol Ther 1999 13 49 57
23. Johnsson F Hatlebakk JG Klintenberg AC Roman J Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn Scand J Gastroenterol 2003 38 347 53
24. Shi G Bruley Des Varannes S Scarpignato C et al. Reflux related symptoms in patienst with normal oesophageal exposure to acid Gut 1995 37 457 64
25. Bate CM Griffin SM Keeling PW et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis Aliment Pharmacol Ther 1996 10 547 55
26. Miner P Orrr W Filippone J et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial Am J Gastroenterol 2002 97 1332 9
27. Kahrilas PJ Miner P Johanson J Mao L Jokubaitis L Sloan S Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease Dig Dis Sci 2005 50 2009 18
28. Fock KM Teo EK Ang TL et al. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia World J Gastroenterol 2005 11 3091 8
29. Lind T Havelund T Carlsson R et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response Scand J Gastroenterol 1997 32 974 9
30. Richter JE Peura D Benjamin SB et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis Arch Intern Med 2000 160 1810 6
31. Katz PO Castell DO Levine D Esomeprazole resolves chronic heartburn in patients without erosive esophagitis Aliment Pharmacol Ther 2003 18 875 82
32. Dean BB Gano AD Knight K Ofman JJ Fass R Effectiveness of proton pump inhibitors in non-erosive reflux disease Clin Gastroenterol Hepatol 2004 2 656 64
33. Richter JE Campbell DR Kahrilas PJ et al. Lansoprazole compared with rantidine for the treatment of nonerosive gastroesophageal reflux disease Arch Intern Med 20000 160 1803 9
34. Gardner JD Gallo-Torres H Sloan S et al. The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive esophagitis Aliment Pharmacol Ther 2003 18 891 905
35. Robertson D Aldersley M Shepherd H Smith CL Patterns of acid reflux in complicated oesophagitis Gut 1987 28 1484 8
36. Watson RG Tham TC Johnson BE McDougall NI Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the ''sensitive oesophagus'' Gut 1997 40 587 90
37. Bardhan KD Muller-Lissner S Bigard A et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine BMJ 1999 318 502 7
38. Talley NJ Venables TL Green JRB et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months Eur J Gastroenterol Hepatol 2002 14 857 63
39. Ponce J Arguello L Bastida G et al. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life and patient satisfaction Dig Dis Sci 2004 49 931 6
40. Bytzer P Blum A DeHerdt D et al. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease Aliment Pharmacol Ther 2004 20 181 8
41. Schlesinger PK Donahue PE Schmidt B Layden TJ Limitations of 24 h intraesophageal pH monitoring in the hospital setting Gastroenterology 1985 89 797 804
42. Murphy DW Yuan Y Castell DO Does the intraesophageal pH probe accurately detect acid reflux? Simultaneous recording with two pH probes in humans Dig Dis Sci 1989 34 649 56
43. Schenk BE Kuipers EJ Klinkenberg-Knoll EC et al. Omeprazole as a diagnostic test in gastroesophageal reflux disease Am J Gastroenterol 1997 11 1997 2000
44. Booth MI Stratford J Dehn TCB Patient self-assessment of test-day symptoms in 24-h pH-metry for suspected gastroesophageal reflux disease Scand J Gastroenterol 2001 36 795 9
45. Sifrim D Holloway R Silny J et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-h pH-impedance recordings Gastroenterology 2001 120 1588 98
46. Vela MF Camacho-Lobato L Srinivasan R et al. Simultaneous intraesophageal and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole Gastroenterology 2001 120 1599 606
47. Pandolfino JE Richter JE Ours T et al. Ambulatory esophageal pH monitoring using a wireless system Am J Gastroenterol 2003 98 740 9
48. Vaezi M Richter JE Stasney CR A randomized, double-blind, placebo-controlled study of acid suppression for the treatment of suspected laryngopharyngeal reflux Gastroenterology 2004 126 Suppl. 2 A-22
49. Harding S Kiljander T Field SK et al. Efficacy of esomeprazole 40 mg twice daily for 16 weeks in adults with asthma: a randomized placebo-controlled trial Gastroenterology 2005 128 Suppl. 2 A-61